ROCKVILLE, Md., Feb. 5, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 2013 BIO CEO & Investor Conference. The conference will be held February 11-12, 2013 at the Waldorf-Astoria Hotel in New York City. Mr. Riley is scheduled to present on Tuesday, February 12, 2013 at 11:00 a.m. (Eastern Time). A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at http://www.veracast.com/webcasts/bio/ceoinvestor2013/06212103.cfm. After the presentation, a replay will be archived and accessible for 30 days at the same website. Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, and its EVP, Research & Development, John Monahan, Ph.D., will be available to participate in one-on-one meetings with investors who are registered to attend the conference. About Synthetic Biologics, Inc. Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. difficile infection, and a series of monoclonal antibodies for the treatment of serious infectious diseases, including pertussis and Acinetobacter. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and is designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com. To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.